VERA THERAPEUTICS INC (VERA)       22.19  +1.78 (+8.72%)

22.19  +1.78 (+8.72%)

US92337R1014 - Common Stock - After market: 22.19 0 (0%)

VERA THERAPEUTICS INC22.19

NASDAQ:VERA (10/4/2022, 7:00:32 PM)+1.78 (+8.72%)

After market: 22.19 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-10 2022-08-10/bmo Earnings (Next) N/A N/A
Ins Owners 12.73% Inst Owners 78.97%
Market Cap 602.27M Shares 27.14M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 84.62
IPO 05-14 2021-05-14

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

VERA Daily chart

Company Profile

Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 29 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate, atacicept, a self-administered fusion protein that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. The company is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus. The firm is also planning to initiate a Phase III clinical trial of atacicept as a potential treatment for patients with LN, a severe renal manifestation of Systemic Lupus Erythematosus (SLE).

Company Info

VERA THERAPEUTICS INC

8000 Marina Boulevard, Suite 120, 3Rd Floor

Brisbane California CALIFORNIA 14623

P: 16507700077.0

CEO: Marshall Fordyce

Employees: 29

Website: https://veratx.com/

VERA News

News Imagea month ago - Vera TherapeuticsVera Therapeutics to Present at Upcoming Conferences in September 2022

BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and...

News Image2 months ago - Vera TherapeuticsVera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Completed enrollment for Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy; topline data now expected to be presented in early Q1...

News Image2 months ago - Vera TherapeuticsVera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

BRISBANE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and...

News Image3 months ago - Vera TherapeuticsVera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Topline results anticipated fourth quarter of 2022...

News Image4 months ago - Vera TherapeuticsVera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

MAU868, a first-in-class monoclonal antibody, was well tolerated in kidney transplant recipients with BK viremiaData presented as oral late breaker at...

News Image4 months ago - Vera TherapeuticsVera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and...

VERA Twits

Here you can normally see the latest stock twits on VERA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example